Title |
Adaptive Immunity to Francisella tularensis and Considerations for Vaccine Development
|
---|---|
Published in |
Frontiers in Cellular and Infection Microbiology, April 2018
|
DOI | 10.3389/fcimb.2018.00115 |
Pubmed ID | |
Authors |
Lydia M. Roberts, Daniel A. Powell, Jeffrey A. Frelinger |
Abstract |
Francisella tularensis is an intracellular bacterium that causes the disease tularemia. There are several subspecies of F. tularensis whose ability to cause disease varies in humans. The most virulent subspecies, tularensis, is a Tier One Select Agent and a potential bioweapon. Although considerable effort has made to generate efficacious tularemia vaccines, to date none have been licensed for use in the United States. Despite the lack of a tularemia vaccine, we have learned a great deal about the adaptive immune response the underlies protective immunity. Herein, we detail the animal models commonly used to study tularemia and their recapitulation of human disease, the field's current understanding of vaccine-mediated protection, and discuss the challenges associated with new vaccine development. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Venezuela, Bolivarian Republic of | 1 | 50% |
Switzerland | 1 | 50% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Scientists | 2 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 38 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 6 | 16% |
Student > Master | 4 | 11% |
Student > Bachelor | 4 | 11% |
Student > Doctoral Student | 4 | 11% |
Student > Ph. D. Student | 3 | 8% |
Other | 6 | 16% |
Unknown | 11 | 29% |
Readers by discipline | Count | As % |
---|---|---|
Immunology and Microbiology | 11 | 29% |
Biochemistry, Genetics and Molecular Biology | 5 | 13% |
Veterinary Science and Veterinary Medicine | 3 | 8% |
Medicine and Dentistry | 3 | 8% |
Agricultural and Biological Sciences | 2 | 5% |
Other | 3 | 8% |
Unknown | 11 | 29% |